-
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices have not delivered on those savings.
-
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients. Here's what the fuss is all about.
-
To drive down costs, insurers are delivering high-priced infusion drugs via third-party pharmacies. Hospitals and clinics are trying to convince states to limit this practice, known as "white bagging."
-
Drug-makers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Florida has already taken action. Now, Congress is finally on board, too, but will it matter?
-
The governor moved quickly to sign a bill that will place restrictions on pharmacy benefit managers. The House and Senate unanimously passed the measure Tuesday.
-
The bill is ready to go to Gov. Ron DeSantis, who during his annual State of the State address in March called for making PBM changes.
-
The House Appropriations Committee on Friday approved a bill that would make a series of changes to regulate PBMs. The Senate unanimously passed its version on Wednesday.
-
Gov. Ron DeSantis plans to add controls on so-called middlemen in prescription transactions. Independent pharmacy owners have complained that PBMs have taken control of the financial market in the business.
-
Gov. Ron DeSantis outlined proposed legislation that would target the health care "middlemen" to try to lower prescription costs. He said his plan will increase transparency and help small drug stores.
-
Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.